Heusden-Zolder, Belgium, 2 March 2021 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing prescription drugs for age-related diseases, announces it has completed a EUR 3.2 million Series A round. The funding is being used to advance the development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
V-Bio Ventures recently announced their second fund, with the first closing already totaling 78 million euros [final close at 110 million euros - Ed.]. As a VC fund with a focus on early-stage life sciences companies, V-Bio will be using Fund 2 to continue supporting European start-ups working on effective healthcare or sustainable agriculture solutions. In this interview, co-founders Christina Takke and Willem Broekaert, along with new Managing Partner Shelley Margetson, share some success stories from V-Bio’s first five years and how they plan to create value for both investors and society in the future.
Brussels, Belgium, 24 February 2021 – Newton Biocapital I (“Newton Biocapital”), a life sciences investment fund active in Europe and Japan focused on chronic diseases, has announced investment in DeuterOncology. Newton Biocapital’s second investment in Flanders, DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies.
Ghent, Belgium, 23 February 2021 - The Ghent company Biogazelle and the medical laboratory Labo Nuytinck (Ghent, Evergem), together with several Flemish companies, have developed a PCR platform with which thousands of saliva samples can be tested daily for the COVID-19 virus. The saliva test costs a third of a classic test.
Micro-chip based µPAC™ LC columns – key component in Vienna IMP study measuring the proteome at picogram level
Ghent, Belgium, 15 February 2021 - PharmaFluidics NV, innovative life sciences instruments player, is excited to announce that researchers of Karl Mechtler’s Group at the Research Institute for Molecular Pathology in Vienna have integrated its ultra-sensitive second generation µPAC™ micro-Chip technology as a key enabler in their advanced Single Cell Proteomics workflow.
Prof. Dr. Pierre Vanderhaeghen from VIB-KU Leuven has been awarded the Generet Prize for Rare Diseases for his research on human brain development. Vanderhaegen’s team have developed an astonishing model for studying rare neurological disorders by successfully integrating human neurons into a mouse brain. The prestigious prize, managed by the King Baudouin Foundation and presented to Vanderhaeghen by HRH Princess Astrid, includes EUR 1 million in funding for further studies.
In mid-2021, research institute VIB will open its brand-new agbiotech incubator. The new complex will provide entrepreneurs with access to high-tech facilities to work on sustainable agricultural innovations, like solutions to make plants more resistant to drought. The incubator will be housed in the former CropDesign site of multinational BASF in Nevele, Belgium.
In 2019, a delegation of Belgian biotechs participated in an economic mission to China led by H.R.H. Princess Astrid. Co-organized with BioCentury’s annual China Healthcare Summit, the mission was a success: three of the participating companies have already signed deals with Chinese collaborators or investors. We spoke with the CEOs of these companies to find out what kind of deals they obtained, and to hear about their experiences of working with Chinese partners.
Heusden-Zolder, Belgium, 2 March 2021 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing prescription drugs for age-related diseases, announces it has completed a EUR 3.2 million Series A round. The funding is being used to advance the development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
V-Bio Ventures recently announced their second fund, with the first closing already totaling 78 million euros [final close at 110 million euros - Ed.]. As a VC fund with a focus on early-stage life sciences companies, V-Bio will be using Fund 2 to continue supporting European start-ups working on effective healthcare or sustainable agriculture solutions. In this interview, co-founders Christina Takke and Willem Broekaert, along with new Managing Partner Shelley Margetson, share some success stories from V-Bio’s first five years and how they plan to create value for both investors and society in the future.
Brussels, Belgium, 24 February 2021 – Newton Biocapital I (“Newton Biocapital”), a life sciences investment fund active in Europe and Japan focused on chronic diseases, has announced investment in DeuterOncology. Newton Biocapital’s second investment in Flanders, DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies.
Ghent, Belgium, 23 February 2021 - The Ghent company Biogazelle and the medical laboratory Labo Nuytinck (Ghent, Evergem), together with several Flemish companies, have developed a PCR platform with which thousands of saliva samples can be tested daily for the COVID-19 virus. The saliva test costs a third of a classic test.
Micro-chip based µPAC™ LC columns – key component in Vienna IMP study measuring the proteome at picogram level
Ghent, Belgium, 15 February 2021 - PharmaFluidics NV, innovative life sciences instruments player, is excited to announce that researchers of Karl Mechtler’s Group at the Research Institute for Molecular Pathology in Vienna have integrated its ultra-sensitive second generation µPAC™ micro-Chip technology as a key enabler in their advanced Single Cell Proteomics workflow.
Prof. Dr. Pierre Vanderhaeghen from VIB-KU Leuven has been awarded the Generet Prize for Rare Diseases for his research on human brain development. Vanderhaegen’s team have developed an astonishing model for studying rare neurological disorders by successfully integrating human neurons into a mouse brain. The prestigious prize, managed by the King Baudouin Foundation and presented to Vanderhaeghen by HRH Princess Astrid, includes EUR 1 million in funding for further studies.
In mid-2021, research institute VIB will open its brand-new agbiotech incubator. The new complex will provide entrepreneurs with access to high-tech facilities to work on sustainable agricultural innovations, like solutions to make plants more resistant to drought. The incubator will be housed in the former CropDesign site of multinational BASF in Nevele, Belgium.
In 2019, a delegation of Belgian biotechs participated in an economic mission to China led by H.R.H. Princess Astrid. Co-organized with BioCentury’s annual China Healthcare Summit, the mission was a success: three of the participating companies have already signed deals with Chinese collaborators or investors. We spoke with the CEOs of these companies to find out what kind of deals they obtained, and to hear about their experiences of working with Chinese partners.